A phase 3 trial of Enfortumab Vedotin in metastatic urothelial cancer patients who received prior checkpoint inhibitor (CPI) therapy.
Phase of Trial: Phase III
Latest Information Update: 08 Feb 2018
At a glance
- Drugs Enfortumab vedotin (Primary)
- Indications Urogenital cancer
- Focus Registrational; Therapeutic Use
- 08 Feb 2018 New trial record
- 06 Feb 2018 According to a Seattle Genetics media release, company is planning to initiate the trial in 2018.